Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Swiss Exchange  -  12:21 2022-09-23 pm EDT
74.36 CHF   -0.92%
09/23NOVARTIS AG : Deutsche Bank gives a Sell rating
MD
09/23NOVARTIS AG : Gets a Sell rating from Barclays
MD
09/23AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis unveils new strategy based on eight multi-billion dollar brands

09/22/2022 | 01:42am EDT
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Novartis unveiled a new strategy on Thursday based on eight drug brands which it said could generate sales in the range of multiple billions of dollars.

Ahead of an investor event, the Swiss company said the currently in-market brands - Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix - each hold multi-billion dollar peak sales potential.

Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine - and had "multiple significant in-market and pipeline assets in each of these areas."

(Reporting by John Revill, editing by Rachel More)


© Reuters 2022
All news about NOVARTIS AG
09/23NOVARTIS AG : Deutsche Bank gives a Sell rating
MD
09/23NOVARTIS AG : Gets a Sell rating from Barclays
MD
09/23AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Add Recommendation
MT
09/23NOVARTIS AG : Credit Suisse keeps a Sell rating
MD
09/23NOVARTIS AG : Goldman Sachs maintains a Buy rating
MD
09/22GLOBAL MARKETS LIVE : Veolia, Meta, Amazon, Salesforce, Target...
MS
09/22SECTOR UPDATE : Health Care Stocks Mixed Premarket Thursday
MT
09/22ETF PREVIEW : ETFs Mixed, Futures Slightly Higher Pre-Bell After Fed Rate Increase, Jobles..
MT
09/22MARKETSCREENER'S WORLD PRESS REVIEW : September 22, 2022
MS
09/22Novartis Says to Adopt 'US-First Mindset' to Become Top-Five Player by 2027
MT
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2022 52 338 M - -
Net income 2022 9 143 M - -
Net Debt 2022 7 589 M - -
P/E ratio 2022 18,3x
Yield 2022 4,39%
Capitalization 165 B 165 B -
EV / Sales 2022 3,31x
EV / Sales 2023 3,24x
Nbr of Employees 108 000
Free-Float 87,1%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 75,81 $
Average target price 92,57 $
Spread / Average Target 22,1%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Non-Executive Chairman
Shreeram Aradhye Chief Medical Officer
Steffen Lang President-Operations
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-7.37%165 486
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392